title: Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.
abstract: Fas and its ligand (FasL) play an important role in apoptosis and carcinogenesis. Therefore, the potential association of polymorphisms in the Fas (-670A>G, rs1800682; -1377G>A, rs2234767) and FasL (-844C>T, rs763110) with cancer risk has been widely investigated. However, all the currently available results are not always consistent. In this work, we performed a meta-analysis to further determine whether carriers of the polymorphisms in Fas and FasL of interest could confer an altered susceptibility to cancer. All relevant data were retrieved by PubMed and Web of Science, and 52 eligible studies were chosen for this meta-analysis. There was no association of the Fas -670A>G polymorphism with cancer risk in the pooled data. For the Fas -1377G>A and FasL -844C>T polymorphisms, results revealed that the homozygotes of -1377A and -844C were associated with elevated risk of cancer as a whole. Further stratified analysis indicated markedly increased risk for developing breast cancer, gastric cancer, and esophageal cancer, in particular in Asian population. We conclude that carriers of the Fas-1377A and the FasL -844C are more susceptible to the majority of cancers than non-carriers.
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Yeqiong
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Bangshun
authors.initials: B
authors.lastname: He
authors.affiliation: Department of Life Sciences, Nanjing Normal University, Nanjing, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Li
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Yuqin
authors.initials: Y
authors.lastname: Pan
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Tianyi
authors.initials: T
authors.lastname: Gao
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Qiwen
authors.initials: Q
authors.lastname: Deng
authors.affiliation: Department of Life Sciences, Nanjing Normal University, Nanjing, China.
authors.forename: Huiling
authors.initials: H
authors.lastname: Sun
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Guoqi
authors.initials: G
authors.lastname: Song
authors.affiliation: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Shukui
authors.initials: S
authors.lastname: Wang
mesh_terms: D016022:Case-Control Studies; D053222:Fas Ligand Protein / Q000235:genetics* / Q000378:metabolism; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012306:Risk; D019014:fas Receptor / Q000235:genetics* / Q000378:metabolism
chemical_list: C491901:FAS protein, human; D053222:Fas Ligand Protein; D019014:fas Receptor